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Figure 1. Knees were mobilized on a CPM devise (A) or immobilized (B), ﬁxed
and examined for the presence of IL-1 by immuno-histochemical staining.
of PM was sufﬁcient for the suppression of proinﬂammatory
genes. Furthermore, the exposure of knees to extended periods
(8 h/day) of PM did not suppress proinﬂammatory gene induction
in the lesions irrespective of the cartilage damage from grade 1
to grade 4.
Conclusions: The expression of proinﬂammatory genes in this
study suggests that the ACL transected knee joint is susceptible
to enhanced degeneration when: (1) the cartilage damage is
greater than grade 2 as evidenced by the presence of proinﬂam-
matory gene expression in grade 3 and 4 lesions post PM and IM
treatment; and (2) the cartilage is exposed to extended periods
of PM or IM irrespective of the extent of cartilage damage (grade
1 to 4). However, low-intensity and low-impact exercise such
as PM may suppress or subside inﬂammation if the cartilage
damage is from grade 1 to 2, and the joint is stabilized during
mobilization. Further, the data suggest that IM treatment was
not able to limit inﬂammation by downregulating expression of
IL-1, MMP-1 and COX-2. Acknowledgements. This work was
supported by NIH grants AR48781 and HD040939.
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Purpose: Montmorency (or Tart) cherries have long been
claimed to be a natural remedy for arthritis and gout. The poten-
tial therapeutic beneﬁt of cherry extracts containing ﬂavonoids
and anthocyanins has been suggested in laboratory models
demonstrating the antioxidant and anti-inﬂammatory (including
the inhibition of both cyclooxygenase 1 and 2) effects of cherry
extracts. Despite anecdotes from osteoarthritis (OA) and rheuma-
toid arthritis (RA) patients, this over-the-counter remedy has
never been formally studied. We have performed an open-label
trial of commercial gel-capsulated cherry extract (Cherry Flex
2000) in knee arthritis (ARCHER study). Each 400 mg soft gel
capsule contains 100 mg Anthocyanins, 20 mg ﬂavones and
30 mg Tannins. Also present are other antioxidants, melatonin,
isoqueritrin, queritrin, vitamin C, vitamin A, alpha linolenic acid
and traces of vitamin E, Beta carotene, folacin and thiamine.
Methods: This was a 20 patient 12 week trial of cherry extract
400 mg daily in patients with osteoarthritis of the knee. Inclu-
sion criteria included age > 40 yrs, active knee pain > 6mos,
a diagnosis of OA of the knee (using ACR clinical or radio-
graphic criteria) and informed consent to participate. Patients
were excluded if they required daily steroids, NSAIDs or narcotic
analgesics, had a history of signiﬁcant knee trauma or surgery
or a diagnosis of ﬁbromyalgia or inﬂammatory arthritis. Patients
were washed out of their NSAID or analgesic therapy and started
on cherry extract 400 mg/d. Rescue analgesia (acetaminophen)
was provided. Outcome variables included the WOMAC (total
and pain), patient and physician global assessment, patient pain,
patient and physician assessment of response, index joint ten-
derness and OA modiﬁed 28 tender joint counts.
Results: Two patients withdrew consent and 18 patients com-
pleted at least 8 weeks of daily cherry extract. This included
13 women and 5 males with a mean age of 55.1 years and
mean disease duration of 6.5 years. WOMAC pain subscales
and total scores improved >20% in 10/13 patients (56%). Similar
levels of improvement were noted for patient and MD global (50-
72%), HAQ, pain and Tender joint counts. WOMAC responders
improved by a mean of 61%. No substantive toxicities were ob-
served, as there was only 1 gastritis and 6 mild infections (URI,
UTI, ﬂu, sinusitis) noted.
Outcome Variable WOMAC Pt. Global MD Global Pain HAQ TJC Index Joint
% >20% improved 56 50 72 56 56 61 56
Conclusions: These interim, open-label results from the
ARCHER study suggest a moderate beneﬁt when a ﬁxed dose
OTC preparation of cherry extract is used in osteoarthritis of the
knee. A 2nd RCT will retest the utility of this compound and
whether a dose response effect may be seen in OA patients.
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Purpose: Traditional Chinese Medicine (TCM) therapies, includ-
ing acupuncture, are increasingly used to treat patients with
symptomatic OA of the knee in Western societies. The scien-
tiﬁc basis for the use of herbal compounds in the treatment of
knee OA, however, is not as well developed. We have found that
the TCM herbal compound Huo-Luo-Xiao-Ling (HLXL) Dan has
signiﬁcant anti-inﬂammatory effects in a preclinical model of in-
ﬂammatory arthritis. Boswellic acids, including Boswellia carterii
(BC), are the main constituents of HLXL Dan, a Chinese herbal
mixture composed of 11 different herbal compounds. In addition,
there is evidence that boswellic acids are efﬁcacious in humans
with inﬂammatory arthritis. We report here the results of a Phase
I pilot study of HLXL Dan in adults with symptomatic knee OA.
Methods: A six-week phase I trial of HLXL Dan at a dose of
5180 mgs daily was conducted in 4 women and 3 men between
the ages of 41 and 72 years (Mean [±SD] 59 [±10] years) with
symptomatic knee OA. This IND study protocol was approved
by the Food and Drug Administration and by the University
of Maryland School of Medicine’s IRB. All participants gave
written informed consent. Participants were screened at week -
1, received HLXL Dan at week 0 (after eligibility was established),
and were then followed on weeks 1, 3, and 6. Average pain over
the past week was assessed with a 100 mm visual analogue
scale (VAS), and the patient’s global assessment of disease
was assessed on a 5-point Likert scale. Adverse events were
monitored by self-report and laboratory testing at all visits. Data
were analyzed in repeated measures mixed models in SAS.
Results: Adherence to the study protocol was high, with all
